Form 8-K - Current report:
SEC Accession No. 0001698530-25-000009
Filing Date
2025-02-21
Accepted
2025-02-21 17:24:54
Documents
15
Period of Report
2025-02-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K xcur-20250214.htm   iXBRL 8-K 33598
2 EX-10.1 exhibit101_cspa21425.htm EX-10.1 184193
3 EX-10.2 exhibit102_rra21425.htm EX-10.2 210979
  Complete submission text file 0001698530-25-000009.txt   622018

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xcur-20250214.xsd EX-101.SCH 1788
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xcur-20250214_lab.xml EX-101.LAB 21629
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xcur-20250214_pre.xml EX-101.PRE 12512
17 EXTRACTED XBRL INSTANCE DOCUMENT xcur-20250214_htm.xml XML 2706
Mailing Address 2430 N. HALSTED ST. CHICAGO IL 60614
Business Address 2430 N. HALSTED ST. CHICAGO IL 60614 847-673-1700
EXICURE, INC. (Filer) CIK: 0001698530 (see all company filings)

EIN.: 815333008 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39011 | Film No.: 25653302
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)